Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential.

Palchaudhuri R, Hergenrother PJ.

ACS Chem Biol. 2011 Jan 21;6(1):21-33. doi: 10.1021/cb100310h. Epub 2010 Dec 23. Review.

2.

RNAi therapeutics: a potential new class of pharmaceutical drugs.

Bumcrot D, Manoharan M, Koteliansky V, Sah DW.

Nat Chem Biol. 2006 Dec;2(12):711-9. Review.

PMID:
17108989
3.

Chemical microarray: a new tool for drug screening and discovery.

Ma H, Horiuchi KY.

Drug Discov Today. 2006 Jul;11(13-14):661-8. Review.

4.

RNA interference: an emerging generation of biologicals.

Shrivastava N, Srivastava A.

Biotechnol J. 2008 Mar;3(3):339-53. doi: 10.1002/biot.200700215. Review.

PMID:
18320564
5.

Small molecule modifiers of the microRNA and RNA interference pathway.

Deiters A.

AAPS J. 2010 Mar;12(1):51-60. doi: 10.1208/s12248-009-9159-3. Epub 2009 Nov 25. Review.

6.
7.

RNA interference as a novel and powerful tool in immunopharmacological research.

Kong Y, Ruan L, Ma L, Cui Y, Wang JM, Le Y.

Int Immunopharmacol. 2007 Apr;7(4):417-26. Epub 2007 Jan 22. Review.

PMID:
17321464
8.

Chemogenomics approaches to novel target discovery.

Gaither LA.

Expert Rev Proteomics. 2007 Jun;4(3):411-9. Review.

PMID:
17552925
9.

Antisense and RNA interference approaches to target validation in pain research.

Kurreck J.

Curr Opin Drug Discov Devel. 2004 Mar;7(2):179-87. Review.

PMID:
15603251
10.

Target validation to biomarker development: focus on RNA interference.

Colombo R, Moll J.

Mol Diagn Ther. 2008;12(2):63-70. Review.

PMID:
18422370
11.

Designing highly active siRNAs for therapeutic applications.

Walton SP, Wu M, Gredell JA, Chan C.

FEBS J. 2010 Dec;277(23):4806-13. doi: 10.1111/j.1742-4658.2010.07903.x. Review.

12.

Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.

Perrimon N, Friedman A, Mathey-Prevot B, Eggert US.

Drug Discov Today. 2007 Jan;12(1-2):28-33. Epub 2006 Oct 30. Review.

PMID:
17198970
13.

Finding the target after screening the phenotype.

Hart CP.

Drug Discov Today. 2005 Apr 1;10(7):513-9. Review.

PMID:
15809197
14.

Gene silencing by chemically modified siRNAs.

Engels JW.

N Biotechnol. 2013 Mar 25;30(3):302-7. doi: 10.1016/j.nbt.2012.07.002. Epub 2012 Jul 20. Review.

PMID:
22820489
15.

RNA interference-based therapeutics: new strategies to fight infectious disease.

López-Fraga M, Wright N, Jiménez A.

Infect Disord Drug Targets. 2008 Dec;8(4):262-73. Review.

PMID:
19075801
16.

Small molecule probes of cellular pathways and networks.

Castoreno AB, Eggert US.

ACS Chem Biol. 2011 Jan 21;6(1):86-94. doi: 10.1021/cb1002976. Epub 2010 Nov 18. Review.

17.

State-of-the-art modified RNAi compounds for therapeutics.

Carstea ED, Hough S, Wiederholt K, Welch PJ.

IDrugs. 2005 Aug;8(8):642-7. Review.

PMID:
16044372
18.

RNA interference screening to detect targetable molecules in hematopoietic stem cells.

Karlsson C, Rak J, Larsson J.

Curr Opin Hematol. 2014 Jul;21(4):283-8. doi: 10.1097/MOH.0000000000000053. Review.

PMID:
24811164
19.

RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes.

Fitzgerald K.

Curr Opin Drug Discov Devel. 2005 Sep;8(5):557-66. Review.

PMID:
16159017
20.

Probing the microRNA pathway with small molecules.

Li Y, Ji P, Jin P.

Bioorg Med Chem. 2013 Oct 15;21(20):6119-23. doi: 10.1016/j.bmc.2013.05.030. Epub 2013 May 25. Review.

Supplemental Content

Support Center